-
Suzhou OSAI Biopharma’s L. crispatus Capsule Meets Phase III Endpoints in Bacterial Vaginosis Study
•
China-based Suzhou OSAI Biopharma Inc., a specialist in live biotherapeutic products (LBPs), has announced that its vaginal L. crispatus live bacteria capsule (Lc262-1) has achieved both primary and secondary endpoints in a Phase III study. The multicenter, randomized, double-blind, placebo-controlled trial involved 320 patients with bacterial vaginosis (BV). Following a…
